// App-Quantinova.ai

2667 : Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target

Researchers

Presenter

  • Tai-Chung Huang

Principal Investigators

  • Shubhada Shashikant Bharne

  • Jevon Cutler

  • Jun Zhong

  • David M. Weinstock

  • Jeffrey W. Tyner

  • Curt I. Civin

  • Akhilesh Pandey

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD

  • Center for Stem Cell Biology & Regenerative Medicine and Departments of Pediatrics and Physiology, University of Maryland School of Medicine, Baltimore, MD

  • McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

  • Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Nucleoside diphosphate kinase A

  • Cluster of Differentiation 25

  • Polo-like kinase 1

  • Cytokine

Drug/Treatment

  • BI-2536

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved